The message that prices for at least 500 medicines have decreased in Kyrgyzstan was received with enthusiasm by society. The Department of Medicines and Medical Devices states that their purpose – regulate prices for all vital medicines. But after studying the list, evidence-based medicine experts were left perplexed – there are only a third of such drugs in it. And another tenth – medicines with unproven effectiveness.
Aida Zurdinova, head of the department of basic and clinical pharmacology at the Faculty of Medicine of KRSU, notes that reducing the cost of drugs cannot be called price regulation. «This forced large pharmacies to reduce prices», — she noted.
«At the same time, the list of medicines that have fallen in price includes about 10 percent — these are drugs that have not been proven or needed at all. Why did they reduce their prices? So that the population «absorbs them further» and turnover occurs? And only one third of the list of vital ones is there».
According to Aida Zurdinova, the question arises why such a large discount was made on antitumor drugs. «The prices of these medicines are very high. How is this possible? Have you made an agreement with the manufacturer? There is a suspicion that the drugs are expiring. In general, it is not clear on what basis the list was compiled. It turns out that the State Committee for National Security gave a list? But the Ministry of Health should advise this», — she noted.
According to the pharmacologist, price regulation could begin with reducing the cost of drugs that are covered by the additional package. This would allow the state to reduce its costs, since the patient pays only part of the price for such drugs.
Read in full